Prescription drug coverage in high cardiovascular risk patients as an important part of the national goals achievement

Soloveva, A.; Яковлев, А. Н.; Yakovlev, A. N.; Villevalde, S.; Звартау, Надежда; Шляхто, Е. В.; Shlyahto, E.V.

doi:10.35576/article_5d651dbc201140.18252870

Cited by 6 publications

(11 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Фармакоэкономические и фармакоэпидемиологические анализы показывают, что прямые медицинские затраты на лечение ОРВИ и гриппа занимают всего 7,5% в структуре всех прямых медицинских затрат при лечении инфекционных заболеваний. При этом затраты на потерю рабочего времени составляют 92,5% от общего экономического ущерба [2,3].…”

Section: актуальностьunclassified

“…модель является аналогом оригинала в наиболее существенных чертах. Поэтому научно обоснованная работа по управлению качеством работы АО должна вестись на основе ее моделирования [2,3,4].…”

Section: подходы к лечению орвиunclassified

“…С другой стороны, информационные модели не несут возможностей для прогноза, вследствие чего такие модели называют формирующими. Эти модели удобно использовать при открытии новых аптек [2,3,4].…”

Section: подходы к лечению орвиunclassified

“…В ситуации традиционного маркетинга наблюдается полный диктат клиентам со стороны аптечной организации, отсутствует учет психологических характеристик потребителя, его эмоциональных реакций на товар и поведение провизора. В настоящее время происходит активизация поиска новых подходов в развитии традиционного маркетинга [2,9].…”

Section: подходы к лечению орвиunclassified

See 3 more Smart Citations

Untitled

2022

SOLO

View full text Add to dashboard Cite

подписной индекс по каталогу "Пресса России" 92326 Современная организация лекарственного обеспечения ¹ 4/2022 Редакционная коллегия Editorial board Ягудина Роза Исмаиловна Главный редактор, Заведующий кафедрой организации лекарственного обеспечения и фармакоэкономики Первого Московского государственного медицинского университета им. И.М. Сеченова, профессор, д.ф.н

show abstract

Section: актуальностьunclassified

Section: подходы к лечению орвиunclassified

See 2 more Smart Citations

Untitled

2022

SOLO

View full text Add to dashboard Cite

show abstract

“…Таким образом, дапаглифлозин может быть рекомендован для широкого применения в соответствии с клиническими рекомендациями [15], в т. ч. в рамках региональных программ льготного ЛО пациентов с ХСН, для скорейшего и полного достижения целей данного ФП "Борьба с сердечно-сосудистыми заболеваниями" и НП "Здравоохранение" в целом. Стратегия льготного ЛО препаратами с доказанной эффективностью у пациентов, характеризующихся высоким риском неблагоприятных событий, представляется стратегически эффективной и экономически оправданной при условии ее подкрепления программами увеличения приверженности пациентов, преодоления врачебной инертности и обеспечения преемственности кардиологической помощи [21].…”

Section: заключениеunclassified

Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases

et al. 2020

View full text Add to dashboard Cite

Aim. To assess the effect of dapagliflozin in patients with heart failure with reduced ejection fraction (HFrEF) on reducing cardiovascular mortality as the main goal of a federal project on the prevention of cardiovascular diseases.Material and methods. All adult Russian patients with a documented NYHA class II-IV HFrEF (EF £40%) were considered the target population. The characteristics of the patients corresponded to those of the Russian Hospital Heart Failure Registry (RUS-HFR). The study looked at an increase in the dapagliflozin use in addition to standard therapy by 10% of patients annually in 2021-2023 and calculated the number of deaths that could be prevented. Cardiovascular mortality curve was created by extrapolation of the DAPA-HF study results using the Kaplan-Meier method. Further, the contribution of prevented deaths with dapagliflozin to the achievement of regional and federal targets for reducing cardiovascular mortality was calculated for 1, 2, and 3 years. Results. In case of 10% annual increase in dapagliflozin use in patients with NYHA class II-IV HFrEF, this will allow:— to prevent an additional 1,736 cardiovascular deaths in the first year, achieving the target of federal project on the prevention of cardiovascular diseases in 2021 by 5,9%;— to prevent an additional 3,784 cardiovascular deaths in the second year, achieving the target of federal project on the prevention of cardiovascular diseases in 2022 by 12,9%;— to prevent an additional 5,485 cardiovascular deaths in the third year, achieving the target of federal project on the prevention of cardiovascular diseases in 2023 by 18,7%.Conclusion. The use of dapagliflozin in patients with HFrEF will reduce mortality from cardiovascular diseases.

show abstract

Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure

et al. 2021

View full text Add to dashboard Cite

Aim. To assess the effect of therapy with sodium glucose co-transporter type 2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction (CHrEF) on the state cardiovascular mortality target indicators.Material and methods. All adult Russian patients with NYHA class II-IV HFrEF (left ventricular ejection fraction ≤40%) were considered as the target population. The characteristics of patients in the study corresponded to those in the Russian Hospital HF Registry (RUS-HFR). The study suggests that the use of dapagliflozin in addition to standard therapy will be expanded by 10% of the patient population annually in 2022-24. Cardiovascular mortality modeling was performed based on the extrapolation of DAPA-HF study result. The number of deaths that can be prevented was calculated when using dapagliflozin in addition to standard therapy. Further, the contribution of prevented deaths with dapagliflozin therapy to the achievement of federal and regional cardiovascular mortality target indicators (1, 2 and 3 years) was calculated.Results. The use of dapagliflozin in addition to standard therapy for patients with NYHA class II-IV CHrEF with the expansion of dapagliflozin therapy by 10% of the patient population annually will additionally prevent 1729 cardiovascular death in the first year. This will ensure the implementation of cardiovascular mortality target indicators in Russia in 2022 by 11,8%. In the second year, 3769 cardiovascular deaths will be prevented, which will ensure the implementation of target indicators in 2023 by 17,2%. In the third year, 5465 cardiovascular deaths prevented, which will ensure the implementation of implementation of target indicators in 2024 by 18,7%.Conclusion. The use of dapagliflozin in addition to standard therapy for patients with NYHA class II-IV CHrEF will ensure the implementation of implementation of target indicators in 2024 by 18,7%.

show abstract

Prescription drug coverage in high cardiovascular risk patients as an important part of the national goals achievement

Cited by 6 publications

References 16 publications

Untitled

Untitled

Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases

Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure

Contact Info

Product

Resources

About